Stock data
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO) reported revenue of US$0.00M and net income of -US$190.89M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$209.31M | -US$190.89M | — |
| 2024 | US$0.02M | — | -US$273.20M | -US$257.59M | — |
| 2023 | US$0.10M | — | -US$327.74M | -US$327.26M | — |
| 2022 | US$0.16M | — | -US$335.54M | -US$340.41M | — |
| 2021 | US$114.09M | — | -US$180.19M | -US$182.05M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$4.64M | -US$42.68M | — |
| 2026-03-31 | — | -US$42.61M | — |
| 2025-12-31 | US$0.00M | -US$38.81M | — |
| 2025-09-30 | US$0.00M | -US$41.40M | — |
| 2025-06-30 | US$0.00M | -US$50.94M | — |
| 2025-03-31 | US$0.00M | -US$59.73M | — |
| 2024-12-31 | US$0.00M | -US$59.94M | — |
| 2024-09-30 | US$0.00M | -US$66.29M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.